• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

尿路上皮乳头状肿瘤的组织学分级:联合分级(双编号分级系统)对可重复性的影响。

Histologic grading of urothelial papillary neoplasms: impact of combined grading (two-numbered grading system) on reproducibility.

机构信息

Department of Pathology, School of Medicine, Dokuz Eylul University, Izmir, Turkey.

出版信息

Virchows Arch. 2011 Jun;458(6):659-64. doi: 10.1007/s00428-011-1072-3. Epub 2011 Apr 12.

DOI:10.1007/s00428-011-1072-3
PMID:21484429
Abstract

The clinical management of tumor patients is often strongly influenced by the tumor grade. The presence of heterogeneity is well recognized in a variety of tumors. Overall grade is based on highest grade area identified within a tumor. Urothelial carcinoma often contains different histological grades within the same tumor. This study investigates the impact of a combined grading system on the reproducibility of papillary urothelial neoplasms. A set prepared for an earlier study consisting of ten cases of each category (papillary urothelial neoplasm of low malignant potential (PUNLMP), LGPUC, and HGPUC) was used. Agreement between pairs of pathologists was evaluated using κ statistics for the combined scoring system. Interobserver agreement was fair to substantial as reflected by κ values ranging from 0.24 to 0.74 (mean κ = 0.43). The combined scores of 2 and 3 which included PUNLMP showed the lowest degree of agreement and when this category was excluded from the analysis, interobserver agreement increased significantly (mean κ = 0.65; ranging from 0.43 to 0.92) in terms of combined scores of 4, 5, and 6. PUNLMP has been shown to be the least reproducible component of a combined scoring system even among experienced observers. Exclusion of PUNLMP from grading scheme seems to improve interobserver variability.

摘要

肿瘤患者的临床管理通常受到肿瘤分级的强烈影响。在各种肿瘤中,异质性的存在是众所周知的。总体分级基于肿瘤内确定的最高分级区域。尿路上皮癌通常在同一肿瘤中包含不同的组织学分级。本研究调查了联合分级系统对乳头状尿路上皮肿瘤可重复性的影响。使用了一套为早期研究准备的组织学样本,包括每种类型的 10 例(低恶性潜能乳头状尿路上皮肿瘤 (PUNLMP)、低级别尿路上皮癌 (LGPUC) 和高级别尿路上皮癌 (HGPUC))。使用 κ 统计量评估了两位病理学家之间的组合评分系统的一致性。κ 值范围为 0.24 至 0.74(平均 κ 值为 0.43),反映了观察者间的一致性为公平至实质性。包括 PUNLMP 的组合评分 2 和 3 显示出最低的一致性,当将该类别从分析中排除时,观察者间的一致性显著增加(平均 κ 值为 0.65;范围为 0.43 至 0.92),即 4、5 和 6 的组合评分。即使在经验丰富的观察者中,PUNLMP 也被证明是联合评分系统中最不可重复的组成部分。将 PUNLMP 从分级方案中排除似乎可以提高观察者间的变异性。

相似文献

1
Histologic grading of urothelial papillary neoplasms: impact of combined grading (two-numbered grading system) on reproducibility.尿路上皮乳头状肿瘤的组织学分级:联合分级(双编号分级系统)对可重复性的影响。
Virchows Arch. 2011 Jun;458(6):659-64. doi: 10.1007/s00428-011-1072-3. Epub 2011 Apr 12.
2
Noninvasive papillary urothelial neoplasia (NIPUN): Renaming cancer.非浸润性乳头状尿路上皮肿瘤(NIPUN):重新命名癌症。
Urol Oncol. 2021 May;39(5):286-290. doi: 10.1016/j.urolonc.2020.12.007. Epub 2021 Jan 1.
3
Expression of MUC1 (Ma695) in noninvasive papillary urothelial neoplasm according to the 2004 World Health Organization classification of the noninvasive urothelial neoplasm. An immunologic tool for the pathologist?根据2004年世界卫生组织非侵袭性尿路上皮肿瘤分类,MUC1(Ma695)在非侵袭性乳头状尿路上皮肿瘤中的表达。这是病理学家的一种免疫工具?
Anal Quant Cytol Histol. 2011 Oct;33(5):277-82.
4
Evaluation of MUC1 and P53 expressions in noninvasive papillary urothelial neoplasms of bladder, their relationship with tumor grade and role in the differential diagnosis.膀胱非侵袭性乳头状尿路上皮肿瘤中MUC1和P53表达的评估、它们与肿瘤分级的关系以及在鉴别诊断中的作用。
Indian J Pathol Microbiol. 2017 Oct-Dec;60(4):510-514. doi: 10.4103/IJPM.IJPM_204_16.
5
Non-invasive papillary urothelial neoplasms: the 2004 WHO/ISUP classification system.非浸润性乳头状尿路上皮肿瘤:2004 年 WHO/国际泌尿病理学会分类系统。
Pathol Int. 2010 Jan;60(1):1-8. doi: 10.1111/j.1440-1827.2009.02477.x.
6
Reappraisal of the papillary urothelial neoplasm of low malignant potential (PUNLMP).低恶性潜能的乳头状尿路上皮肿瘤(PUNLMP)的再评估。
Histopathology. 2020 Oct;77(4):525-535. doi: 10.1111/his.14192. Epub 2020 Sep 13.
7
Study of the reproducibility of the 2004 World Health Organization classification of urothelial neoplasms.2004年世界卫生组织尿路上皮肿瘤分类的可重复性研究。
Indian J Pathol Microbiol. 2015 Jan-Mar;58(1):59-61. doi: 10.4103/0377-4929.151189.
8
Cytologic diagnosis of low-grade papillary urothelial neoplasms (low malignant potential and low-grade carcinoma) in the context of the 1998 WHO/ISUP classification.1998年世界卫生组织/国际泌尿病理学会分类背景下低级别乳头状尿路上皮肿瘤(低度恶性潜能和低级别癌)的细胞学诊断
Diagn Cytopathol. 2003 Apr;28(4):186-90. doi: 10.1002/dc.10263.
9
Reproducibility of the 1998 World Health Organization/International Society of Urologic Pathology classification of papillary urothelial neoplasms of the urinary bladder.1998年世界卫生组织/国际泌尿病理学会膀胱乳头状尿路上皮肿瘤分类的可重复性
Virchows Arch. 2003 Dec;443(6):734-40. doi: 10.1007/s00428-003-0905-0. Epub 2003 Oct 8.
10
Histologic grading of urothelial carcinoma: a reappraisal.尿路上皮癌的组织学分级:再评价。
Hum Pathol. 2012 Dec;43(12):2097-108. doi: 10.1016/j.humpath.2012.01.008. Epub 2012 Apr 26.

引用本文的文献

1
Recent Advances in the Classification of Bladder Cancer - Updates from the 5th Edition of the World Health Organization Classification of the Urinary and Male Genital Tumors.膀胱癌分类的最新进展——来自世界卫生组织《泌尿系统及男性生殖器官肿瘤分类》第5版的更新
Bladder Cancer. 2023 Mar 31;9(1):1-14. doi: 10.3233/BLC-220106. eCollection 2023.
2
Investigation toward the economic feasibility of personalized medicine for healthcare service providers: the case of bladder cancer.医疗服务提供者个性化医疗的经济可行性调查:以膀胱癌为例。
Front Med (Lausanne). 2024 May 14;11:1388685. doi: 10.3389/fmed.2024.1388685. eCollection 2024.
3

本文引用的文献

1
The pathologist's mean grade is constant and individualizes the prognostic value of bladder cancer grading.病理学家的平均分级是恒定的,可使膀胱癌分级的预后价值个体化。
Eur Urol. 2010 Jun;57(6):1052-7. doi: 10.1016/j.eururo.2009.09.022. Epub 2009 Sep 11.
2
Prognostic accuracy of individual uropathologists in noninvasive urinary bladder carcinoma: a multicentre study comparing the 1973 and 2004 World Health Organisation classifications.个体尿路上皮癌病理学家在非浸润性膀胱癌中的预后准确性:比较 1973 年和 2004 年世界卫生组织分类的多中心研究。
Eur Urol. 2010 May;57(5):850-8. doi: 10.1016/j.eururo.2009.03.052. Epub 2009 Mar 31.
3
Development and reliability of the histological THROMBEX-classification rule for thrombotic emboli of acute ischemic stroke patients.
急性缺血性中风患者血栓性栓子的组织学THROMBEX分类规则的制定与可靠性
Neurol Res Pract. 2021 Sep 20;3(1):50. doi: 10.1186/s42466-021-00149-6.
4
First approach to distinguish between cardiac and arteriosclerotic emboli of individual stroke patients applying the histological THROMBEX-classification rule.应用组织学 THROMBEX 分类规则,初步区分个体脑卒中患者的心脏性和动脉粥样硬化性栓子。
Sci Rep. 2021 Apr 19;11(1):8433. doi: 10.1038/s41598-021-87584-2.
5
Characterization of mRNA Expression and Endogenous RNA Profiles in Bladder Cancer Based on The Cancer Genome Atlas (TCGA) Database.基于癌症基因组图谱(TCGA)数据库的膀胱癌 mRNA 表达和内源性 RNA 谱特征分析。
Med Sci Monit. 2019 Apr 25;25:3041-3060. doi: 10.12659/MSM.915487.
6
Level of mitoses in non-muscle invasive papillary urothelial carcinomas (pTa and pT1) at initial bladder biopsy is a simple and powerful predictor of clinical outcome: a multi-center study in South Korea.初次膀胱活检时非肌层浸润性乳头状尿路上皮癌(pTa和pT1)的有丝分裂水平是临床结局的一个简单而有力的预测指标:韩国的一项多中心研究
Diagn Pathol. 2017 Jul 24;12(1):54. doi: 10.1186/s13000-017-0639-y.
Comparison of 1998 WHO/ISUP and 1973 WHO classifications for interobserver variability in grading of papillary urothelial neoplasms of the bladder. Pathological evaluation of 258 cases.
1998年世界卫生组织/国际泌尿病理学会(WHO/ISUP)与1973年世界卫生组织膀胱乳头状尿路上皮肿瘤分级观察者间变异性分类的比较。258例病例的病理评估。
Urol Int. 2007;78(4):338-44. doi: 10.1159/000100839.
4
Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma.细胞周期生物标志物在非肌层浸润性膀胱移行细胞癌中的预测价值
J Urol. 2007 Feb;177(2):481-7; discussion 487. doi: 10.1016/j.juro.2006.09.038.
5
Histologic grading of noninvasive papillary urothelial neoplasms.非浸润性乳头状尿路上皮肿瘤的组织学分级
Eur Urol. 2007 Apr;51(4):889-97; discussion 897-8. doi: 10.1016/j.eururo.2006.10.037. Epub 2006 Oct 27.
6
Papillary urothelial neoplasm of low malignant potential: evolving terminology and concepts.低恶性潜能乳头状尿路上皮肿瘤:不断演变的术语和概念
J Urol. 2006 Jun;175(6):1995-2003. doi: 10.1016/S0022-5347(06)00267-9.
7
Comparison of WHO 1973, WHO/ISUP 1998, WHO 1999 grade and combined scoring systems in evaluation of bladder carcinoma.世界卫生组织1973年、世界卫生组织/国际泌尿病理学会1998年、世界卫生组织1999年分级系统及联合评分系统在膀胱癌评估中的比较
Urol Int. 2004;73(3):201-8. doi: 10.1159/000080828.
8
Papillary urothelial neoplasm of low malignant potential: reliability of diagnosis and outcome.低度恶性潜能的乳头状尿路上皮肿瘤:诊断可靠性与预后
BJU Int. 2004 Jun;93(9):1228-31. doi: 10.1111/j.1464-410X.2004.04848.x.
9
FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma.FGFR3和P53是尿路上皮细胞癌发病机制中不同遗传途径的特征。
Cancer Res. 2004 Mar 15;64(6):1911-4. doi: 10.1158/0008-5472.can-03-2421.
10
Reproducibility of the 1998 World Health Organization/International Society of Urologic Pathology classification of papillary urothelial neoplasms of the urinary bladder.1998年世界卫生组织/国际泌尿病理学会膀胱乳头状尿路上皮肿瘤分类的可重复性
Virchows Arch. 2003 Dec;443(6):734-40. doi: 10.1007/s00428-003-0905-0. Epub 2003 Oct 8.